Elanco Animal Health Incorporated Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Elanco Animal Health Incorporated (ELAN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$17.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-24
- Elanco Animal Health Incorporated valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2021-03-31 was $2.00M.
- Elanco Animal Health Incorporated valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$17.00M.
- Elanco Animal Health Incorporated valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$77.00M, a 182.80% decline from fiscal 2023.
- Elanco Animal Health Incorporated valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $93.00M, a 16.25% increase from fiscal 2022.
- Elanco Animal Health Incorporated valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $80.00M, a 5.26% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|
| 2025-12-31 | -$17.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | -$77.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $93.00M 10-K · filed 2026-02-24 | |
| 2022-12-31 | $80.00M 10-K · filed 2025-02-25 | |
| 2021-12-31 | $76.00M 10-K · filed 2024-02-26 | |
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-09 | |
| 2020-12-31 | $72.00M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |